「イノバン」4製品は、協和キリンが製造販売承認を取得し販売を行ってきました。今後はテルモが製造販売承認を承継します。また、「ドブタミン」3製品はテルモが製造販売承認を取得し、これまで協和キリンに販売を委託していました。販売移管により今後はテルモが自社販売を行います。
TopWe are pleased to announce that Terumo Co., Ltd. (Headquarters: Shibuya-ku, Tokyo; President: Hikaru Samejima) will inherit manufacturing and sales approval for 4 products of the dopamine hydrochloride injection “Inovan” from Kyowa Kirin Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Masashi Miyamoto), and will also receive a sales transfer for 3 products of the diluted dobutamine hydrochloride injection “Dobutamine”.
“Inovan” and “dobutamine” are pressure-boosting drugs (drugs to improve acute circulatory failure) used to raise patients' blood pressure during the perioperative period (before, during, and after surgery).
They all come in various dosage forms, but only the Inovan injection 0.1% syringe, Inovan injection 0.3% syringe, Inovan injection 0.3% syringe, Inovan injection 0.6% syringe, the dobutamine continuous intravenous 50 mg syringe “KKC,” the dobutamine continuous intravenous 150 mg syringe “KKC,” and the dobutamine continuous intravenous injection 300 mg syringe “KKC” are on the market as pre-filled syringes*.
Kyowa Kirin has obtained manufacturing and sales approval for the 4 “Inovan” products and has been selling them. From now on, Terumo will take over the manufacturing and sales approval. Furthermore, Terumo has obtained manufacturing and sales approval for the 3 “dobutamine” products, and sales have been outsourced to Kyowa Kirin until now. Due to the transfer of sales, Terumo will carry out in-house sales in the future.
Terumo sells antihypertensive drugs and anesthetic analgesics as preparations that are widely used during the perioperative period. By adding pressure-boosting drugs to the lineup, we aim to expand our pharmaceutical portfolio and further strengthen our ability to propose solutions during the perioperative period.
*As of the end of November 2024, Terumo research.
Inovan injection 100mg
Inovan note 0.1% syringe
Inovan note 0.3% syringe
Inovan note 0.6% syringe
(efficacy or effect)
acute circulatory failure (cardiogenic shock, hemorrhagic shock)
It is used for acute circulatory failure conditions such as the following.
1. Anuria, oliguria, or a condition where diuresis cannot be obtained with diuretics
2. state of increased pulse rate
3. A state where side effects are observed or favorable responses are not obtained due to other cardiotonic and vasopressor agents
[Products receiving sales transfers ※Sales names after transfer are shown in parentheses]
Dobutamine continuous intravenous 50 mg syringe “KKC” (dobutamine continuous intravenous 50 mg syringe “Termo”)
Dobutamine continuous intravenous 150 mg syringe “KKC” (Dobutamine continuous intravenous 150 mg syringe “Termo”)
Dobutamine continuous intravenous 300mg syringe “KKC” (dobutamine continuous intravenous 300mg syringe “Termo”)
(efficacy or effect)
Increased cardiac contractility in acute circulatory failure
Terumo Overview
Terumo is a medical device manufacturer with a history of 100 years, with the philosophy of “contributing to society through medical care.” Headquartered in Japan, we have operations in over 160 countries and regions around the world, and over 30,000 associates (employees) work every day to deliver innovative solutions.
It began with the manufacture of domestically produced thermometers, and has continued to support the medical infrastructure since its establishment. Currently, we provide a wide range of products and services related to catheter treatment, cardiac surgery, drug administration, diabetes management, peritoneal dialysis, blood transfusions, cell therapy, etc.
Terumo aims to be a company of value to society at large, including patients and health care workers.
Press releases are intended to provide our stakeholders with fair and timely information. The product information included in the text (including those under development) is not intended to attract customers or provide medical advice.
Furthermore, statements relating to the future, such as earnings forecasts, etc. are based on information currently obtained by the Company and certain assumptions judged to be reasonable, and are not intended to be realized by the Company. Please be aware that actual performance etc. may fluctuate due to various factors. Key factors that can influence actual performance include economic conditions surrounding Terumo's business area, exchange rate fluctuations, and competitive conditions.
News Release Top
